• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pembrolizumab immunotherapy for relapsed CNS Lymphoma.

作者信息

Graber Jerome J, Plato Benjamin, Mawad Raya, Moore Daniel J

机构信息

Department of Neurology, Benjamin and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, WA, USA.

Alvord Brain Tumor Center, University of Washington, Seattle Cancer Care Alliance, Seattle, WA, USA.

出版信息

Leuk Lymphoma. 2020 Jul;61(7):1766-1768. doi: 10.1080/10428194.2020.1742903. Epub 2020 Mar 23.

DOI:10.1080/10428194.2020.1742903
PMID:32204633
Abstract
摘要

相似文献

1
Pembrolizumab immunotherapy for relapsed CNS Lymphoma.帕博利珠单抗用于复发性中枢神经系统淋巴瘤的免疫治疗。
Leuk Lymphoma. 2020 Jul;61(7):1766-1768. doi: 10.1080/10428194.2020.1742903. Epub 2020 Mar 23.
2
Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab.采用抗CD20抗体利妥昔单抗对复发性中枢神经系统淋巴瘤进行脑室内治疗。
Haematologica. 2004 Jun;89(6):753-4.
3
Should dose-intense immunochemotherapy be the new standard of care for primary CNS lymphoma?
J Clin Oncol. 2014 Mar 10;32(8):857-8. doi: 10.1200/JCO.2013.53.7084. Epub 2014 Feb 3.
4
Salvage immuno-chemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: a preliminary study.
Leuk Lymphoma. 2007 Jul;48(7):1429-33. doi: 10.1080/10428190701370605.
5
Pembrolizumab for the treatment of diffuse large B-cell lymphoma.派姆单抗治疗弥漫性大 B 细胞淋巴瘤。
Expert Opin Biol Ther. 2019 Nov;19(11):1119-1126. doi: 10.1080/14712598.2019.1659777. Epub 2019 Aug 28.
6
Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement.GMALL-B-ALL/NHL2002 方案在伴或不伴 CNS 累及的伯基特白血病/淋巴瘤和侵袭性非霍奇金淋巴瘤中的疗效。
Eur J Haematol. 2019 Mar;102(3):241-250. doi: 10.1111/ejh.13199. Epub 2019 Jan 20.
7
Controversies in primary CNS lymphoma.原发性中枢神经系统淋巴瘤的争议
Expert Rev Neurother. 2005 Jul;5(4):459-64. doi: 10.1586/14737175.5.4.459.
8
Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?非霍奇金淋巴瘤的中枢神经系统预防：对象、措施及时机？
Curr Oncol Rep. 2015 Jun;17(6):25. doi: 10.1007/s11912-015-0450-4.
9
[Therapeutic management of central nervous system lymphomas in a single hematological institute].[单一血液学机构中中枢神经系统淋巴瘤的治疗管理]
Orv Hetil. 2009 Oct 18;150(42):1937-44. doi: 10.1556/OH.2009.28703.
10
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.帕博利珠单抗治疗晚期黑色素瘤或 PD-L1 阳性、晚期、复发、难治性实体瘤或淋巴瘤的儿科患者（KEYNOTE-051）：一项开放标签、单臂、1-2 期临床试验的中期分析。
Lancet Oncol. 2020 Jan;21(1):121-133. doi: 10.1016/S1470-2045(19)30671-0. Epub 2019 Dec 4.

引用本文的文献

1
Safety and efficacy of programmed cell death-1 inhibitors in relapsed immune-privileged site lymphoma: A systematic review and meta-analysis.程序性细胞死亡蛋白1抑制剂在复发性免疫豁免部位淋巴瘤中的安全性和疗效：一项系统评价和荟萃分析。
PLoS One. 2025 Apr 29;20(4):e0319714. doi: 10.1371/journal.pone.0319714. eCollection 2025.
2
Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study.信迪利单抗（抗 PD-1 抗体）联合大剂量甲氨蝶呤、替莫唑胺和利妥昔单抗（抗 CD20 抗体）治疗原发性中枢神经系统淋巴瘤：一项 2 期研究。
Signal Transduct Target Ther. 2024 Sep 4;9(1):229. doi: 10.1038/s41392-024-01941-x.
3
Comparative analyses of immune cells and alpha-smooth muscle actin-positive cells under the immunological microenvironment between with and without dense fibrosis in primary central nervous system lymphoma.
原发性中枢神经系统淋巴瘤中致密纤维化与无致密纤维化免疫微环境下免疫细胞和α-平滑肌肌动蛋白阳性细胞的比较分析。
Brain Tumor Pathol. 2024 Oct;41(3-4):97-108. doi: 10.1007/s10014-024-00488-7. Epub 2024 Aug 26.
4
Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma.高危弥漫性大B细胞淋巴瘤患者中枢神经系统预防的最新进展。
Exp Hematol Oncol. 2024 Jan 3;13(1):1. doi: 10.1186/s40164-023-00467-2.
5
A novel Bruton's tyrosine kinase inhibitor JDB175 shows potent efficacy to suppress central nervous system lymphoma.一种新型布鲁顿酪氨酸激酶抑制剂JDB175在抑制中枢神经系统淋巴瘤方面显示出强大疗效。
MedComm (2020). 2023 Nov 4;4(6):e424. doi: 10.1002/mco2.424. eCollection 2023 Dec.
6
Checkpoint inhibition in hematologic malignancies.血液系统恶性肿瘤中的检查点抑制
Front Oncol. 2023 Oct 17;13:1288172. doi: 10.3389/fonc.2023.1288172. eCollection 2023.
7
The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors.原发性和转移性脑肿瘤免疫检查点抑制剂免疫治疗的现状
Antibodies (Basel). 2023 Apr 4;12(2):27. doi: 10.3390/antib12020027.
8
Bruton's tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review.布鲁顿酪氨酸激酶抑制剂在原发性中枢神经系统淋巴瘤治疗中的应用：一篇综述。
Front Oncol. 2022 Nov 17;12:1034668. doi: 10.3389/fonc.2022.1034668. eCollection 2022.
9
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL).欧洲神经肿瘤学会（EANO）原发性中枢神经系统淋巴瘤（PCNSL）治疗指南。
Neuro Oncol. 2023 Jan 5;25(1):37-53. doi: 10.1093/neuonc/noac196.
10
Novel insights into the biomarkers and therapies for primary central nervous system lymphoma.对原发性中枢神经系统淋巴瘤生物标志物和治疗方法的新见解。
Ther Adv Med Oncol. 2022 May 4;14:17588359221093745. doi: 10.1177/17588359221093745. eCollection 2022.